Ignite Creation Date:
2025-12-24 @ 2:39 PM
Ignite Modification Date:
2025-12-28 @ 1:12 PM
Study NCT ID:
NCT00668759
Status:
COMPLETED
Last Update Posted:
2009-12-15
First Post:
2008-04-25
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase III Superiority Study of Vernakalant vs Amiodarone in Subjects With Recent Onset Atrial Fibrillation
Sponsor:
Advanz Pharma
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
VERI-305-AMIO
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Sheila Grant, VP Product Development and Product team leader, Vernakalant
Old Organization:
Cardiome Pharma Corp.